<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750424</url>
  </required_header>
  <id_info>
    <org_study_id>HIC-1209010842</org_study_id>
    <nct_id>NCT01750424</nct_id>
  </id_info>
  <brief_title>3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites</brief_title>
  <official_title>3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess scar-formation and wound healing following the use of
      autologous fat grafting in facial reconstruction patients. Patients who have undergone facial
      reconstruction in the last 3 months will be randomized into two groups, one receiving fat
      grafting and one not receiving any intervention. These patients will continue to follow-up in
      our clinic for one year, with 3-D images taken at each follow-up visit to assess scar
      formation and wound healing. Assessment of the scar will be undertaken by both healthcare
      personnel as well as general lay public. We hypothesize that patients undergoing fat grafting
      to the wound site will achieve a more aesthetically appealing result, with less scarring and
      improved wound healing as judged by both the general public and healthcare professionals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of local and regional skin flaps are used for reconstruction of skin defects on the
      face with the intention of full wound closure, healing, and scar minimization. Scarring is an
      unavoidable consequence of wound healing, especially after significant facial reconstruction.
      Fibroblasts migrate to the injurious site where they proliferate and deposit collagen. The
      collagenous proteins serve to fill in the wound defect and allow epithelial cells to
      accumulate and repopulate the skin surface. The collagenous base is subsequently exchanged
      for various types of collagen and is crosslinked. Although scar formation is an important
      component of wound healing, patients develop scars differently based upon location and
      biology of the subject. Excessive scar formation may result from excessive collagen
      production and inadequate collagen remodeling (Gurtner).

      Much effort has focused on minimizing scar formation. Such techniques have included rigorous
      sterilization techniques, smaller, more linear incisions, and incisions that follow normal
      tension lines in the skin to name only a few. However, these techniques have been mostly
      limited to intraoperative or pre-operative measures. And while successful in minimizing scar
      burden, these techniques do not address scar management post operatively.

      Wound healing and scar formation follow complex biological processes dependent on
      inflammatory cells and growth factors. It has been shown in utero that fetal wounds are
      capable of scarless healing during a phase of gestation when wounds heal with a paucity of
      inflammatory cells (Soo, Frantz). This principle was further studied in immune deficient mice
      lacking both macrophages and neutrophils, which are critical to the inflammatory response.
      Within this experiment, both groups of mice (immunodeficient and normal mice) healed the
      wounds, the immunodeficient mice did so in a scarless manner (Mori, Martin). Extrapolating
      this information to current surgical patients, the development of an immunomodulating measure
      is critical to inhibiting and managing scar formation.

      Adipose derived mesenchymal stem cells (ADSCs) have been studied with regard to their role in
      the wound healing and scar formation process and have shown great promise. In experimental
      studies, ADSCs have shown to promote angiogenesis, granulation and reepithelialization of the
      overlying wound (Ebrahimian). Whether directly or indirectly through these processes, the
      ADSCs also improve the appearance of resultant scars by decreasing size, contrast of scar
      color, and improving pliability of the scar (Blanton, Yun). However, it is not to be confused
      that all adipose tissue is equivalent with ADSCs. Rather, ADSCs are a particular line of
      cells found within adipose tissue that have the unique capability of differentiating into a
      variety of types of tissues, from bone to cartilage to further adipose tissue (Zuk). These
      cells are capable of being harvested and cultured from adipose tissue within subjects and
      then subsequently injected into the wound site of interest.

      Fat grafting is a similar but less involved technique that harvests autologous adipose tissue
      but does not use cell culture techniques to isolate ADSCs from other cell lineages. Fat
      grafting has long been used as a technique concurrently with facial reconstruction procedures
      and facial rejuvenation procedures as a &quot;filler&quot; of sorts for facial augmentation as early as
      1893 (Miller). The fat injected into the face serves as a volume expander to correct defects
      related to loss of muscle or bone, such as in micrognathia. Since those initial trials, the
      technique has been widely expanded and honed to provide the best possible contouring. In
      addition to the filler aspects and results of the procedure, the technique has been observed
      to improve skin quality in injection sites, improve pigmentation irregularities, and even
      improve appearance of long standing scars. However, a formal study of fat grafting's
      potential of improved wound healing and minimization of scar formation has never been
      undertaken.

      Although not identical to the process of injection of autologous ADSCs, the process of fat
      grafting has the capabilities of providing some number of ADSCs that were in the adipose
      harvest. Additionally, the process itself has been shown in the past to improve previously
      existing scars and improve the quality of skin overlying injection sites (Coleman).
      Therefore, it is logical to assume that injection of autologous fat will improve wound
      healing and minimize scar formation in patients undergoing the procedure through effects of
      ADSCs within the harvested tissue.

      With the advent of advanced 3-D imaging technology, we are now able to obtain high-quality,
      high-resolution images to document and detail stages of wound healing and scar formation.
      Therefore, we will be able to determine through observer analysis whether the process of fat
      grafting changes the formation and quality of scars over time.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Color, Vascularity, Distortion, Contour, and Appearance of Scar through use of Manchester Scar Scale</measure>
    <time_frame>3 months post-fat grafting</time_frame>
    <description>An independent group of observers/evaluators, consisting of medical students and other non-faculty medical personnel as well as general lay observers, will be asked to view the 3-D images from each time point, evaluate the aesthetic outcome, and grade the scars presented in each case. Scales used will be the Manchester Scar Scale, which has been used previously for photographic scar assessment, as well as a more lay-person's version of the Manchester Scar scale created for the use of an average observer. These forms assess the color, hypertrophy, vascularity, etc of the scar as compared to surrounding skin. The data collected will be analyzed using appropriate statistical software and/or calculations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color, Vascularity, Distortion, Contour, and Appearance of Scar through use of Manchester Scar Scale</measure>
    <time_frame>6 months post-fat grafting</time_frame>
    <description>An independent group of observers/evaluators, consisting of medical students and other non-faculty medical personnel as well as general lay observers, will be asked to view the 3-D images from each time point, evaluate the aesthetic outcome, and grade the scars presented in each case. Scales used will be the Manchester Scar Scale, which has been used previously for photographic scar assessment, as well as a more lay-person's version of the Manchester Scar scale created for the use of an average observer. These forms assess the color, hypertrophy, vascularity, etc of the scar as compared to surrounding skin. The data collected will be analyzed using appropriate statistical software and/or calculations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color, Vascularity, Distortion, Contour, and Appearance of Scar through use of Manchester Scar Scale</measure>
    <time_frame>12 months post-fat grafting</time_frame>
    <description>An independent group of observers/evaluators, consisting of medical students and other non-faculty medical personnel as well as general lay observers, will be asked to view the 3-D images from each time point, evaluate the aesthetic outcome, and grade the scars presented in each case. Scales used will be the Manchester Scar Scale, which has been used previously for photographic scar assessment, as well as a more lay-person's version of the Manchester Scar scale created for the use of an average observer. These forms assess the color, hypertrophy, vascularity, etc of the scar as compared to surrounding skin. The data collected will be analyzed using appropriate statistical software and/or calculations.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Scar Formation</condition>
  <condition>Autologous Fat Grafting</condition>
  <arm_group>
    <arm_group_label>Fat Grafted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-fat grafted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Fat Grafting</intervention_name>
    <arm_group_label>Fat Grafted</arm_group_label>
    <other_name>Fat Grafting</other_name>
    <other_name>Adipose Grafting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Subjects in this arm will only be followed up and have no procedure performed.</description>
    <arm_group_label>Non-fat grafted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects

          -  Facial reconstruction surgery in the last 3 months

        Exclusion Criteria:

          -  Age less than 18 years

          -  Patients undergoing skin grafting

          -  Patients undergoing secondary intent closure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Steinbacher, MD, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Soo C, Hu FY, Zhang X, Wang Y, Beanes SR, Lorenz HP, Hedrick MH, Mackool RJ, Plaas A, Kim SJ, Longaker MT, Freymiller E, Ting K. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol. 2000 Aug;157(2):423-33.</citation>
    <PMID>10934147</PMID>
  </reference>
  <reference>
    <citation>Frantz FW, Bettinger DA, Haynes JH, Johnson DE, Harvey KM, Dalton HP, Yager DR, Diegelmann RF, Cohen IK. Biology of fetal repair: the presence of bacteria in fetal wounds induces an adult-like healing response. J Pediatr Surg. 1993 Mar;28(3):428-33; discussion 433-4.</citation>
    <PMID>8468658</PMID>
  </reference>
  <reference>
    <citation>Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008 Jan 21;205(1):43-51. doi: 10.1084/jem.20071412. Epub 2008 Jan 7.</citation>
    <PMID>18180311</PMID>
  </reference>
  <reference>
    <citation>Cooper L, Johnson C, Burslem F, Martin P. Wound healing and inflammation genes revealed by array analysis of 'macrophageless' PU.1 null mice. Genome Biol. 2005;6(1):R5. Epub 2004 Dec 23.</citation>
    <PMID>15642097</PMID>
  </reference>
  <reference>
    <citation>Ebrahimian TG, Pouzoulet F, Squiban C, Buard V, Andr√© M, Cousin B, Gourmelon P, Benderitter M, Casteilla L, Tamarat R. Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing. Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):503-10. doi: 10.1161/ATVBAHA.108.178962. Epub 2009 Feb 5.</citation>
    <PMID>19201690</PMID>
  </reference>
  <reference>
    <citation>Blanton MW, Hadad I, Johnstone BH, Mund JA, Rogers PI, Eppley BL, March KL. Adipose stromal cells and platelet-rich plasma therapies synergistically increase revascularization during wound healing. Plast Reconstr Surg. 2009 Feb;123(2 Suppl):56S-64S. doi: 10.1097/PRS.0b013e318191be2d.</citation>
    <PMID>19182664</PMID>
  </reference>
  <reference>
    <citation>Yun IS, Jeon YR, Lee WJ, Lee JW, Rah DK, Tark KC, Lew DH. Effect of human adipose derived stem cells on scar formation and remodeling in a pig model: a pilot study. Dermatol Surg. 2012 Oct;38(10):1678-88. doi: 10.1111/j.1524-4725.2012.02495.x. Epub 2012 Jul 16.</citation>
    <PMID>22804839</PMID>
  </reference>
  <reference>
    <citation>Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002 Dec;13(12):4279-95.</citation>
    <PMID>12475952</PMID>
  </reference>
  <reference>
    <citation>Miller JJ, Popp JC. Fat hypertrophy after autologous fat transfer. Ophthalmic Plast Reconstr Surg. 2002 May;18(3):228-31.</citation>
    <PMID>12021657</PMID>
  </reference>
  <reference>
    <citation>Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):108S-120S.</citation>
    <PMID>16936550</PMID>
  </reference>
  <reference>
    <citation>Gurtner GC. Wound Healing: Normal and Abnormal. In: Thorne C, Beasley RW, Aston SJ, Bartlett SP, Gurtner GC, Spear SL, eds. Grabb and Smith's Plastic Surgery. Sixth ed: Philadelphia, PA : Lippincott Williams &amp; Wilkins; 2007.</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Fat Grafting</keyword>
  <keyword>Adipose Grafting</keyword>
  <keyword>3-D imaging</keyword>
  <keyword>Manchester Scar Scale</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

